All products have special prices for bulk purchase, please contact for more details if required.

Cat. No.: OCRISPR1-500 (for 500pmol)

Cat. No.: OCRISPR1-2500 (for 2500pmol)

Description

OpenCRISPR‑1 is the world’s first gene editor designed entirely by artificial intelligence. The Profluent research team began by mining 26.2 terabases of microbial genomic data to construct the CRISPR‑Cas Atlas, a database containing more than 1.24 million CRISPR operons—over four times the Cas9 sequence diversity found in UniProt. Using this unprecedented dataset, the team fine‑tuned the protein language model ProGen2 to generate 4.8 million novel CRISPR‑associated protein sequences, from which OpenCRISPR‑1 emerged as the top‑performing candidate after rigorous screening and functional validation.

OpenCRISPR‑1 is a 1,380‑amino‑acid nuclease that preserves the canonical bilobed architecture of type II Cas9 proteins, yet differs from SpCas9 at more than 400 amino‑acid positions. Its sequence similarity to any known natural CRISPR protein does not exceed 86%, highlighting its highly divergent, AI‑designed nature. Despite this divergence, AlphaFold2 structural predictions show that OpenCRISPR‑1 retains all essential functional domains, including the HNH and RuvC nuclease domains. It recognizes the same 5'-NGG-3' PAM as SpCas9 and is fully compatible with standard SpCas9 sgRNAs, making it a plug‑and‑play replacement for existing SpCas9 workflows.

Functional studies demonstrate that OpenCRISPR‑1 achieves on‑target editing efficiencies comparable to SpCas9 in human cells—for example, 56.4% editing efficiency at the HEK3 locus—while offering dramatically improved specificity. Whole‑genome off‑target profiling shows a 95% reduction in off‑target editing, and all detected off‑target sites are a subset of those generated by SpCas9, with no new off‑target patterns introduced. Notably, OpenCRISPR‑1 lacks several T‑cell–recognized immunogenic epitopes present in bacterial Cas9 proteins, suggesting it may exhibit lower immunogenicity than SpCas9 in therapeutic contexts.